


Supplementary figures:

Supplementary Fig. 1.

(a-e) FACS staining of IL-2 activated NK cells with tumor cell surface molecules fusion proteins ANPEP-Ig [1] (a), PDGFRa-Ig [2] (b), HAVcR-1-Ig [3] (c), CD46-Ig [4] (d) and EFNB2-Ig [5] (e). (f-h) FACS staining of Raji cells with commercial anti-Nectin4 (f), anti-Nectin2 (g), anti-PVR (h). (i,j) FACS analysis of parental BW cells (BW) or BW cells expressing (i) TIGIT (designated as BW TIGIT), or (j) DNAM1 (designated BW DNAM1). The empty black histograms represent the staining of the indicated transfectants with the appropriate mAbs and the gray filled histograms represent the staining of the parental BW cells with the indicated mAbs. (k) FACS staining of IL-2 activated NK

cells. Cells were stained with anti-TIGIT. **(l-n)** FACS staining of MDA-MB-453 cells with commercial anti-Nectin4 **(l)**, anti-Nectin2 **(m)**, anti-PVR **(n)**. Figures show one representative experiment out of three performed. Grey filled histogram represents background staining with secondary antibody only; black line histogram represents




specific binding as indicated.

15


Supplementary Fig. 2.

(a-f) Graph depicting the Mean Fluorescence Intensity (MFI) values summarizing the staining repeats for the figures shown in the main text. Figure referenced from the main text is indicated above each graph. * $p < 0.05$, N.S-not significant.



Supplementary Fig. 3.

(a-h) Graph depicting the Mean Fluorescence Intensity (MFI) values summarizing the staining repeats for the figures shown in the main text. Figure referenced from the main text is indicated above each graph. *p<0.05.



25

Supplementary Fig. 4.

Graph depicting the Mean Fluorescence Intensity (MFI) values summarizing the staining repeats for figure 5b shown in the main text. N.S-not significant.

References:

1. Larkin SET, Holmes S, Cree IA, Walker T, Basketter V, Bickers B, et al. Identification of markers of prostate cancer progression using candidate gene expression. *Br J Cancer* [Internet]. Nature Publishing Group; 2012 [cited 2019 Apr 30];106:157–65. Available from: <http://www.nature.com/articles/bjc2011490> 30
2. Ramos AH, Dutt A, Mermel C, Perner S, Cho J, LaFargue CJ, et al. Amplification of chromosomal segment 4q12 in non-small cell lung cancer. *Cancer Biol Ther* [Internet]. 2009 [cited 2019 Apr 30];8:2042–50. Available from: <http://www.landesbioscience.com/journals/cbt/article/9764/> 35
3. Wang Y, Martin TA, Jiang WG. HAVcR-1 expression in human colorectal cancer and its effects on colorectal cancer cells in vitro. *Anticancer Res* [Internet]. International Institute of Anticancer Research; 2013 [cited 2019 Apr 30];33:207–14. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/23267147> 40
4. Juhl H, Helmig F, Baltzer K, Kalthoff H, Henne-Bruns D, Kremer B. Frequent Expression of Complement Resistance Factors CD46, CD55, and CD59 on Gastrointestinal Cancer Cells Limits the Therapeutic Potential of Monoclonal Antibody 17-1A [Internet]. *J. Surg. Oncol.* 1997. Available from: <https://onlinelibrary.wiley.com/doi/pdf/10.1002/%28SICI%291096-9098%28199703%2964%3A3%3C222%3A%3AAID-JSO9%3E3.0.CO%3B2-C> 45
5. Kataoka H, Tanaka M, Kanamori M, Yoshii S, Ihara M, Wang Y-J, et al. Expression profile of EFNB1, EFNB2, two ligands of EPHB2 in human gastric cancer. *J Cancer Res Clin Oncol* [Internet]. Springer-Verlag; 2002 [cited 2019 Apr 30];128:343–8. Available from: <http://link.springer.com/10.1007/s00432-002-0355-0> 50